Intersect ENT Valuation
| XENTDelisted Stock | USD 28.24 0.00 0.00% |
At this time, the firm appears to be overvalued. Intersect ENT retains a regular Real Value of $23.82 per share. The prevalent price of the firm is $28.24. Our model calculates the value of Intersect ENT from evaluating the firm fundamentals such as Return On Asset of -17.82, current valuation of 961.95 M, and Return On Equity of -181.73 as well as inspecting its technical indicators and probability of bankruptcy. In general, most investors encourage acquiring undervalued assets and selling overvalued assets since, at some point, asset prices and their ongoing real values will come together.
Overvalued
Today
Please note that Intersect ENT's price fluctuation is very steady at this time. Calculation of the real value of Intersect ENT is based on 3 months time horizon. Increasing Intersect ENT's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Our valuation method for Intersect ENT is useful when determining the fair value of the Intersect stock, which is usually determined by what a typical buyer is willing to pay for full or partial control of Intersect ENT. Since Intersect ENT is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Intersect Stock. However, Intersect ENT's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 28.24 | Real 23.82 | Hype 28.24 |
The real value of Intersect Stock, also known as its intrinsic value, is the underlying worth of Intersect ENT Company, which is reflected in its stock price. It is based on Intersect ENT's financial performance, assets, liabilities, growth prospects, management team, or industry conditions. The intrinsic value of Intersect ENT's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence Intersect ENT's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of Intersect ENT helps investors to forecast how Intersect stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Intersect ENT more accurately as focusing exclusively on Intersect ENT's fundamentals will not take into account other important factors: Intersect ENT Valuation Ratios as Compared to Competition
Comparative valuation techniques use various fundamental indicators to help in determining Intersect ENT's current stock value. Our valuation model uses many indicators to compare Intersect ENT value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Intersect ENT competition to find correlations between indicators driving Intersect ENT's intrinsic value. More Info.Intersect ENT is rated first in price to earning category among related companies. It is rated first in price to book category among related companies . Comparative valuation analysis is a catch-all model that can be used if you cannot value Intersect ENT by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Intersect ENT's Stock. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Intersect ENT's earnings, one of the primary drivers of an investment's value.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Intersect ENT's worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Intersect ENT and how it compares across the competition.
About Intersect ENT Valuation
The delisted stock valuation mechanism determines the current worth of Intersect ENT on a weekly basis. We use both absolute as well as relative valuation methodologies to arrive at the intrinsic value of Intersect ENT. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of Intersect ENT based exclusively on its fundamental and basic technical indicators. By analyzing Intersect ENT's financials, quarterly and monthly indicators, and its related drivers such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of Intersect ENT's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of Intersect ENT. We calculate exposure to Intersect ENT's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to Intersect ENT's related companies.Intersect ENT, Inc. operates as an ear, nose, and throat medical technology company in the United States. Intersect ENT, Inc. was incorporated in 2003 and is headquartered in Menlo Park, California. Intersect Ent operates under Medical Devices classification in the United States and is traded on NASDAQ Exchange. It employs 406 people.
8 Steps to conduct Intersect ENT's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates Intersect ENT's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct Intersect ENT's valuation analysis, follow these 8 steps:- Gather financial information: Obtain Intersect ENT's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine Intersect ENT's revenue streams: Identify Intersect ENT's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research Intersect ENT's industry and market trends, including the size of the market, growth rate, and competition.
- Establish Intersect ENT's growth potential: Evaluate Intersect ENT's management, business model, and growth potential.
- Determine Intersect ENT's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate Intersect ENT's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Intersect ENT Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines. Note, investing in growth stocks can be very risky. If the company such as Intersect ENT does not do well, investors take a loss on the stock when it is time to sell. Also, because growth stocks typically do not pay dividends, the only opportunity an investor has to make money on their investment is when they eventually sell their shares.
| Shares Percent Shares Out | 4.31% | |
| Revenue Growth | 7.40% | |
| Forward Price Earnings | -16.81 | |
| Float Shares | 28.38M | |
| Shares Short Prior Month | 1.52M |
Check out Your Current Watchlist to better understand how to build diversified portfolios. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in board of governors. You can also try the Portfolio Holdings module to check your current holdings and cash postion to detemine if your portfolio needs rebalancing.
Other Consideration for investing in Intersect Stock
If you are still planning to invest in Intersect ENT check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Intersect ENT's history and understand the potential risks before investing.
| Odds Of Bankruptcy Get analysis of equity chance of financial distress in the next 2 years | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Volatility Analysis Get historical volatility and risk analysis based on latest market data | |
| Money Managers Screen money managers from public funds and ETFs managed around the world |